MD20140112A2 - Analogi carba-nucleozidici 2'-substituiţi pentru tratamentul antiviral - Google Patents

Analogi carba-nucleozidici 2'-substituiţi pentru tratamentul antiviral

Info

Publication number
MD20140112A2
MD20140112A2 MDA20140112A MD20140112A MD20140112A2 MD 20140112 A2 MD20140112 A2 MD 20140112A2 MD A20140112 A MDA20140112 A MD A20140112A MD 20140112 A MD20140112 A MD 20140112A MD 20140112 A2 MD20140112 A2 MD 20140112A2
Authority
MD
Moldova
Prior art keywords
nucleoside analogs
antiviral treatment
compounds
substituted carba
carba
Prior art date
Application number
MDA20140112A
Other languages
English (en)
Russian (ru)
Other versions
MD4496C1 (ro
MD4496B1 (ro
Inventor
Michael O`Neil Hanrahan Clarke
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20140112A2 publication Critical patent/MD20140112A2/ro
Publication of MD4496B1 publication Critical patent/MD4496B1/ro
Publication of MD4496C1 publication Critical patent/MD4496C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/30—Vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Invenţia se referă la compuşi cu Formula I,,precum şi la compoziţii farmaceutice care conţin compuşii cu Formula I şi metode pentru tratarea infecţiilor cu virusul Orthomyxoviridae prin administrarea acestor compuşi.Compuşii, compoziţiile şi metodele propuse sunt utile în particular pentru tratamentul infecţiilor cu virusul gripal uman.
MDA20140112A 2012-03-13 2013-03-11 Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral MD4496C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610411P 2012-03-13 2012-03-13
PCT/US2013/030196 WO2013138236A1 (en) 2012-03-13 2013-03-11 2'- substituted carba-nucleoside analogs for antiviral treatment

Publications (3)

Publication Number Publication Date
MD20140112A2 true MD20140112A2 (ro) 2015-02-28
MD4496B1 MD4496B1 (ro) 2017-07-31
MD4496C1 MD4496C1 (ro) 2018-02-28

Family

ID=47997868

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140112A MD4496C1 (ro) 2012-03-13 2013-03-11 Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral

Country Status (19)

Country Link
US (4) US9481704B2 (ro)
EP (4) EP3932931A1 (ro)
JP (3) JP6242378B2 (ro)
KR (1) KR102068856B1 (ro)
CN (2) CN104185638A (ro)
AU (2) AU2013232378B2 (ro)
CA (1) CA2866381C (ro)
EA (2) EA201791916A1 (ro)
ES (3) ES2878087T3 (ro)
HK (2) HK1207083A1 (ro)
IL (2) IL234586A (ro)
IN (1) IN2014DN08505A (ro)
MD (1) MD4496C1 (ro)
MX (1) MX355267B (ro)
NZ (1) NZ629996A (ro)
PL (1) PL2834258T3 (ro)
PT (1) PT2834258T (ro)
SI (1) SI2834258T1 (ro)
WO (1) WO2013138236A1 (ro)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
US8633198B1 (en) 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
MX356509B (es) 2011-12-22 2018-05-30 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
ES2878087T3 (es) * 2012-03-13 2021-11-18 Gilead Sciences Inc Análogos de carba-nucleósido 2-sustituidos para el tratamiento antiviral
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG10201804571TA (en) * 2012-03-21 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2872485T (pt) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Grupo auxiliar assimétrico
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
KR101868128B1 (ko) * 2013-12-11 2018-06-18 난트 홀딩스 아이피, 엘엘씨 인플루엔자 a rna-의존성 rna 폴리머라제의 저분자 저해제
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
CR20160400A (es) 2014-02-06 2016-11-07 Riboscience Llc Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
CR20170157A (es) 2014-09-26 2017-07-03 Riboscience Llc Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US10953029B2 (en) 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
TWI778052B (zh) 2017-04-24 2022-09-21 美商共結晶製藥公司 流感病毒複製之抑制劑
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
TWI821343B (zh) 2018-07-27 2023-11-11 美商共結晶製藥公司 流感病毒複製之抑制劑
JP7472108B2 (ja) 2018-09-10 2024-04-22 コクリスタル ファーマ，インコーポレイテッド ピリドピラジン系及びピリドトリアジン系インフルエンザウィルス複製阻害剤
EP3887355A1 (en) 2018-11-26 2021-10-06 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
US20230181615A1 (en) * 2020-03-22 2023-06-15 Inspirmed Corp. Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases
EP4129291A4 (en) * 2020-03-30 2024-04-10 FUJIFILM Toyama Chemical Co., Ltd. CORONAVIRUS INFECTION TREATMENT MEDICATION
CN111956630A (zh) * 2020-08-20 2020-11-20 大连理工大学 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
PE20240654A1 (es) * 2021-08-20 2024-04-04 Shionogi & Co Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) * 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (ro) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) * 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5388571A (en) * 1987-07-17 1995-02-14 Roberts; Josephine A. Positive-pressure ventilator system with controlled access for nebulizer component servicing
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
CA2444415A1 (en) 1991-07-02 1993-01-21 Nektar Therapeutics Method and device for delivering aerosolized medicaments
US5261538A (en) * 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) * 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) * 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
RS50236B (sr) * 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
WO2003062256A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
JP4398631B2 (ja) * 2002-07-12 2010-01-13 富山化学工業株式会社 新規なピラジン誘導体またはその塩並びにそれらを含有する抗ウイルス剤
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
AU2008251555B2 (en) 2007-05-10 2012-08-30 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
NO2937350T3 (ro) * 2008-04-23 2018-06-09
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US10023600B2 (en) * 2009-09-21 2018-07-17 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
HUE032252T2 (en) * 2009-09-21 2017-09-28 Gilead Sciences Inc 2'-fluoro-substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) * 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
AP3269A (en) * 2010-07-22 2015-05-31 Gilead Sciences Inc Methods and compounds for treating paramyxoviridaevirus infections
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
ES2878087T3 (es) 2012-03-13 2021-11-18 Gilead Sciences Inc Análogos de carba-nucleósido 2-sustituidos para el tratamiento antiviral

Also Published As

Publication number Publication date
JP2017206528A (ja) 2017-11-24
AU2017279590A1 (en) 2018-01-18
JP2019069986A (ja) 2019-05-09
ES2878087T3 (es) 2021-11-18
EP3351552A1 (en) 2018-07-25
SI2834258T1 (sl) 2017-04-26
EA201491548A1 (ru) 2015-02-27
PT2834258T (pt) 2017-04-07
MD4496C1 (ro) 2018-02-28
US10941177B2 (en) 2021-03-09
IN2014DN08505A (ro) 2015-05-15
AU2013232378B2 (en) 2017-09-28
CN104185638A (zh) 2014-12-03
EP3210993B1 (en) 2018-12-12
EP3351552B1 (en) 2021-05-19
HK1207083A1 (en) 2016-01-22
EP3932931A1 (en) 2022-01-05
KR102068856B1 (ko) 2020-01-21
JP6525441B2 (ja) 2019-06-05
US20210253622A1 (en) 2021-08-19
US9481704B2 (en) 2016-11-01
KR20140135820A (ko) 2014-11-26
IL256397A (en) 2018-02-28
PL2834258T3 (pl) 2017-07-31
EP3210993A1 (en) 2017-08-30
MD4496B1 (ro) 2017-07-31
CN106749272B (zh) 2019-08-30
ES2621217T3 (es) 2017-07-03
EA201791916A1 (ru) 2018-07-31
NZ629996A (en) 2016-10-28
HK1256856A1 (zh) 2019-10-04
CN106749272A (zh) 2017-05-31
US20130243725A1 (en) 2013-09-19
JP6242378B2 (ja) 2017-12-06
JP2015509983A (ja) 2015-04-02
EA028928B9 (ru) 2018-05-31
WO2013138236A1 (en) 2013-09-19
EA028928B1 (ru) 2018-01-31
MX2014011009A (es) 2014-10-13
CA2866381C (en) 2020-03-24
EP2834258A1 (en) 2015-02-11
AU2013232378A1 (en) 2014-09-25
ES2709071T3 (es) 2019-04-15
CA2866381A1 (en) 2013-09-19
US11787832B2 (en) 2023-10-17
IL234586A (en) 2017-12-31
MX355267B (es) 2018-04-12
US20170114086A1 (en) 2017-04-27
US20190016749A1 (en) 2019-01-17
EP2834258B1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
MD20140112A2 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratamentul antiviral
PH12015501385A1 (en) Autotaxin inhibitors
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA201790781A2 (ru) Противовирусные соединения
CA2807584C (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014502524B1 (en) Carboxylic acid compounds
UA116083C2 (uk) Похідні пурину для лікування вірусних інфекцій
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
GEP20166438B (en) Imidazopyrrolidinone compounds
EA201591244A1 (ru) Противовирусные соединения
MD4602B1 (ro) Inhibitori ai virusului hepatic C
EA201790963A1 (ru) Противовирусные соединения
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TN2014000112A1 (en) Ep1 receptor ligands
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
IN2014DN10683A (ro)

Legal Events

Date Code Title Description
FG4A Patent for invention issued